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Control of Cellular Influx in Lung and Its
Role in Pulmonary Toxicology
by William S. Lynn*
The pulmonary influx of cytotoxic inflammatory cells, normally, in response to external toxins, is now
thought to be etiologic in many ofthe disease syndromes ofman, such as bronchitis and emphysema. Many
types ofeffectorinflammatory cells are involved, e.g., eosinophils, neutrophils, T-lymphocytes, monocytes.
The diseases are characterized either by tissue destruction or by tissue hyperplasia. Agents which initiate
the influx andcytotoxic secretions by these cells are legion and in general are not cell-specific. They include
agents, such as phorbol esters, formyl peptides-complement fragments, elastin fragments, fatty acids
(leukotrienes) as well as many uncharacterized excretions of inflammatory cells themselves, which react
with specific receptors on the inflammatory cells, and secreted proteins such as fibronectin. Other agents,
such as linoleic acid, digitonin and hydroxy fatty acids which are not bound by specific receptors also
activate motility ofinflammatory cells. The precise role ofthe above multiple cytotoxins in specific cellular
fluxes in most pulmonary disease remains undefined.
Similarly, the mechanism ofcytotoxicity used by specific invading cells in specific pulmonary syndromes
remains unclear. In general, macrophages are thought to destroy using specific proteases, neutrophils use
oxidant radicals and proteases and eosinophils use basic surface active peptides. T-cells kill by unknown
mechanisms. However, in specific clinical syndromes, it is usually not clear which cell is the cytotoxic
culprit, nor is the mechanism of destruction usually known.
The specific cellular influx and efflux ofinflammatory
cellsinto specific components ofthe mammalianlungis a
major characteristic of several pulmonary toxic syn-
dromes. Thisis also true, ofcourse, for mostpulmonary
clinical syndromes (e.g., bronchitis, emphysema, cig-
arette smoke poisoning, acute respiratory distress
syndromes) or the many granulomatous syndromes
(eosinophilic granuloma, Wegner's granuloma, Boeck's
sarcoid) observed in man. Each of these syndromes is
characterized by influx and accumulation of specific
inflammatory cells into specific pulmonary compart-
ments.
There is now considerable information concerning
the nonspecific influx of inflammatory cells into dam-
aged tissues. However, little understanding concerning
specific cellular influxes is available, and essentially no
dataare available concerningcellulareffluxfromhealing
tissues. An understanding of the clinical syndromes
listed above in which the residence time of specific
inflammatory cells in lung can be very long-of the
order of years-is crucial to establish therapeutic or
etiologic approaches to these diseases.
Multiple substances, whether inhaled or injected
intratracheally or intravenously, will cause the accumu-
lation of various inflammatory cells in various areas of
the mammalian lung. For example, intratracheal injec-
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tion of cotton extract, various other phenols, irritant
substances or various gases will cause a rapid influx (4
hr) of polymorphonuclear leukocytes (PMNL) into air-
ways (1). Similarly, intravenous injection of Freund's
adjuvant, silica or aluminium silicate particles orinhala-
tion of cigarette smoke, ozone or elevated concentra-
tions of oxygen (2,3) results in accumulation of PMNL
acutely and of macrophages subsequently into alveolar
and interstitial compartments. Intratracheal injection
of a-quartz in germ-free rats causes a delayed accumu-
lation (3 mo) ofmacrophages without a preceding influx
of PMNL (4).
In other species, however, e.g., fowl or amphibia,
inflammatory cells do not invade the lungwith exposure
to intratracheal silica, intravenous Freund's adjuvant or
hyperbaric oxygen (5,6). In fact, fowl lungs suffer no
observable acute or chronic damage from hyperbaric
oxygen or from intratracheal injection of silica or
Freund's adjuvant (6). Thus, it is clear that different
mechanisms exist, in various species, for controllingthe
efflux and accumulation ofspecific inflammatory cells in
localized areas of the lung.
Since in these species those lungs are not damaged by
known lung toxins, there is also no inflammatory cell
influx, it is possible that much of the lung cell damage
seen in mammalian lung diseases is the result of the
cytotoxic capabilities ofthe inflammatory system itself.
The above observations, suggesting that the chronic
lung damage seen clinically and after toxic exposures ofW S. LYNN
mammals-but not nonmammalian species-may be
the result ofthe destructive capabilities ofthe invading
inflammatory cells themselves have raised three thera-
peutically important questions (7): What controls the
influx and efflux of inflammatory cells into lung? What
factors control the cytotoxic mechanisms ofthese cells?
And most importantly, are these cytotoxic mechanisms
of these inflammatory cells really responsible for the
observed tissue destruction or hypertrophy seen in
various clinical syndromes, e.g., emphysema, chronic
bronchitis, asthma, interstitial fibrosis, and various
chronic granulomatous syndromes, which appear to be
clearly related to exposure to respirable toxins?
Control of Inflammatory Cell Motility
Specific Cytotaxins
Molecules of two major types (Table 1) are known to
activate motility in vitro of inflammatory mammalian
cells but not in other species (5). These two types are
polypeptides and oxidized fatty acids (8-10).
Peptides. Thepeptidesincludesyntheticpeptides as
well as many naturally occurring ones, e.g., various
formylated peptides (9), specific fragments from com-
plement (C5a) (11), and helper peptides (12), a-globu-
lins, collagen (13), elastin (14) and fibronectin (15).
These peptides are also known to bind to different cell
surface receptors present in varying amounts on
granulocytes but not on lymphocytes (16,17). Binding
ofthese receptors to theirrespective ligands is stoichio-
metrically related to degree of motility. Although
optimal motility is observed when these peptides are
presented tothe cellin aconcentration gradient (chemo-
taxis), these peptides also activate motility in the
absence of a concentration gradient (chemokinesis).
The magnitude of the nondirected migratory response
in vitro depends on the concentration of cells, i.e., the
freedom of the cells to move laterally, rather than
vertically, through filters (18).
Chemical alteration ofthe peptide bond by N-alkyla-
tion of the synthetic chemotaxin, formyl-met-phe,
causes a complete loss ofbinding to the formyl peptide
receptor. However, some ofthe biologic activities, e.g.,
chemokinesis, inhibition of O2- production, of these
peptide analogs remain (19). This indicates that the
peptide bond itself is not necessary for all cell biologic
functions ofchemotactic peptides. Likewise, the clinical
specificity of the receptor for the synthetic formyl
peptides has been shown to be nonspecific. Pyrazolon
anti-inflammagens, e.g., phenyl butazone, specifically
inhibit binding of F-met-leu-phe to its receptor on
human neutrophils (20).
Many uncharacterized biologic peptides with chemo-
attractant activities are also produced by various cells,
e.g., lymphocytes, macrophages, mast cells and tumor
cells in culture (21-24). It is not known if all these
various cytotaxins have specific receptors, but it is clear
that these agents possess marginal specificity for
different celltypes. Both polymorphonuclearleukocytes
(PMNL), monocytes and alveolar or peritoneal macro-
phages are all stimulated by these peptides. However, it
was recently shown that peptides containing desmosine
(14), as well as desmosine itself are much more
chemotactic for blood monocytes than for blood PMNL
or alveolar macrophages. Fragments offibronectin also
appear to be somewhat specific cytotaxins for fibro-
blasts (15). An uncharacterized neutral substance of
low molecular weight produced by human alveolar
macrophages upon stimulation exhibit some specificity
for neutrophils (25). The biologically derived acidic
tetrapeptide has also been shown to be somewhat
specific for motility of mammalian eosinophils (21), but
it is not clear ifthis tetrapeptide is a major cytotaxin in
vivo, since eosinophils also respond to many ofthe above
peptides as well.
Fatty Acids. Two biologic unsaturated fatty acids,
Table 1. Cytotaxin specificity.
Activity of cellsa
Cytotaxins PMNL Macrophages Monocytes Eosinophils
Peptides
C5a + + + +
Collagen fragments +
Elastin +
Eosinophil tetrapeptide + +
N-Formyl + + + +
N1-Formyl N2-alkyl + +
Unsaturated fatty acids and lipids
Arachidonic + +
Linoleic +
Monohydroxy C20 + +
Dihydroxy C20 +
Prostaglandin E1 +
Alveolar macrophage cytotaxin + + + +
Platelet activating factor +
a + = major cytotactic activity.
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arachidonic and linoleic and theirproducts, appear tobe
the major fatty acids involved in in vivo cytotaxis (10,
26,27) . Many of the oxidation products of arachidonic
acid, e.g., prostaglandin E1, the various monohydro-
peroxy and monohydroxy, i.e., 5-, 12- and 15-, eicosa-
tetraenoic acids, and 5,12-dihydroxyeicosatetraenoic
acid (8,28) as well as many uncharacterized photon-
activated oxidation products of arachidonic acid (10)
all exhibit chemoattractant properties in vitro. Arachi-
donic acid itselfis also apowerful nonspecific attractant,
even under conditions in which many of its metabolic
pathways are inhibited. However, since arachidonic acid
is so metabolically active, this acid does not usually
accumulate in amounts sufficient to be physiologically
active (29). Linoleic acid, however, does accumulate in
considerable amounts, followinginjury, in body cavities,
e.g., airways, pleura, and peritoneum (27). Various
oxidation products of arachidonic acid, especially the
hydroxy acids (30), also accumulate. In contrast to the
peptides, however, these fatty acids are not bound by
specific cell surface receptors on human PMNL (26).
The mechanism by which these fatty acids activate
motility is chemokinetic in type (18). Thus, chemotaxis
which is the result of specific ligand-receptor inter-
actions is usually not observed with the fatty acids.
The fatty acids, like the peptides, also possess
cellular specificity. In fact, the only agent, thus far
describedthatspecificallyattractsalveolarmacrophages
but not blood granulocytes is linoleic acid (18). This
mechanism for linoleic acid attraction ofmacrophages is
chemokinetic. Since the time course forinflux and efflux
of linoleic acid following injury in both airways of
rabbits and in pleura of rats (26) closely parallels the
influx and efflux of macrophages, it is likely that this
chemokinetic mechanism which is stimulated by linoleic
acid is operative in macrophage motility in vivo.
The source of this extravascular linoleic acid is
probably the resident macrophages themselves. Stimu-
lation of the isolated resident alveolar or pleural
macrophages in vitro by agents such as zymosan or
silica particles, phorbol esters, or calcium ionophores,
causes a massive efflux of linoleic and other fatty acids
from these cells. These fatty acids are derived almost
exclusively from the phosphatidylcholines within these
cells (26). Since essentially no arachidonic acid is
liberated from these cells and since much of the
secreted chemoattractant activities in these extra-
cellularlavages can be accounted for as linoleic acid, itis
likely thatresident extravascular macrophages account,
at least in part, for the accumulation ofthe cell-specific
cytotaxin, linoleic acid, in injured extravascular spaces
in mammals.
The above concept of the role of the secretions of
resident inflammatory cells in extravascular spaces of
mammals is supported by recent observations on other
species. Essentially, no macrophages can be removed
by lung lavage from fowl (6) (chickens) or amphibia
(bull frogs) (5). These species also do not accumulate
pulmonary inflammatory cells when exposed to hyper-
baric oxygen or intratracheal respirable silica particles;
nor does linoleic acid accumulate after exposure in
airways of these two species; nor do these species
suffer the hemorrhagic edematous lung damage seen
in mammals exposed to hyperbaric oxygen (5). Thus,
these observations on other species support the con-
tention that the massive influx of inflammatory cells
seen in mammalian lung, following exposure to oxidant
or other types of toxins, is specifically involved in
the resultant mammalian tissue damage.
Summary
It now appears that many inflammatory cells, as well
as most extracellular structures (elastin, collagen and
other secretory proteins) are the source of the active
fatty acids or peptides, which can attract inflammatory
cells, including fibroblasts, either specifically or non-
specifically. The peptide fragments specifically attract
PMNL eosinophils or monocytes; the lipid fragments
activateresident extravascularmacrophages. The source
of these biologically active products of proteases or
phospholipases in largely the inflammatory cells them-
selves.
Species which do not accumulate resident macro-
phages in alveoli, e.g., fowl or amphibia, when exposed
to mammalian toxins such as 02 or silica, do not develop
tissue damage upon exposure.
Inflammatory Cell Cytotoxicity
The above considerations implicating the inflamma-
tory system as etiologic in many environmental toxic
syndromes make it imperative that we understand how
the cytotoxic potential of the inflammatory system is
controlled. Three major cytotoxic systems are known,
i.e., neutral proteases (31), neutral phospholipases and
their inhibitors (26,32) and the oxidant-radical-pro-
ducing system (33). The latter system is localized
primarily in blood granulocytes, whereas the two
hydrolase systems are localized primarily in macro-
phages.
The immune system, ofcourse, with its vast array of
monoclonal specificity is primarily concerned with
focusing the above cytotoxic systems. With its capacity
to recognize specific cells, either foreign or domestic, it
directs the cytotoxic cells to their assigned target. This
immunologic recognition and direction is beyond the
scope of this review and is not further discussed. It is
clear, however, that the cytotoxic system can work
equally well either on its own direction or as directed by
the immune system. This discussion is concerned only
with the self-directed cytotoxic mechanisms of gran-
ulocyte and macrophages.
Oxidant Radical Production
Oxygen-derived radicals produce hydroxylated pur-
ines or pyrimidines, lipid hydroperoxides, auto-oxidized
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products of thiols or amines, as well as depolymerized
polysaccharides (33). Under ambient conditions, the
major cellular source of extracellular oxidants (O2-,
H202, OH) is PMNL. Macrophages and fibroblast
secrete considerably lesser amounts (34). Under hy-
peroxic conditions, however, it is likely that oxidant
radical production (by cytoplasmic oxidases, mitochon-
drial oxidases and microsomal oxidases) by most cells
canincrease toadegreethattheintracellularscavengers
(superoxide dismutase, glutathione reductase, catalase,
prostaglandin and thromboxane synthetase and lipoxy-
genase) as well as the extracellular scavenger, super-
oxide dismutase (35), fail to control intracellular
concentrations. This leads to the various types of cell
damage as indicated above, with the result that all cells
can be potentially destroyed by internal oxidants.
At ambient conditions, cytotoxic destruction by
extracellular oxidants is most likelythe work ofPMNL.
The control of oxidant secretion in PMNL remains
poorly understood. Almost any surface-active molecule,
e.g., hydrophobic peptides, unsaturated fatty acids,
digitonin, phorbol esters, calcium ionophores, cyto-
chalasins, etc., will all activate this process (36,37). 02
appears to be the major excretory product (38), but the
toxic species is the hydroxyl radical (39). The only
known way to inhibit this process is to remove a bound
protease from these cells, either by extensive washing,
or by displacement ofthe protease by small amounts of
formylated peptides or cytotactic fatty acids or by
inhibition of the protease by addition of protease
inhibitors (40). However, once the secretion of radicals
is fully activated, e.g., by ionophores, digitonin or
phorbol esters, the protease inhibitors are ineffective.
Also, there are no other known inhibitors. Secretion of
destructive oxidant radicals by leukocytes, therefore, is
a process which is readily triggered by very low
concentrations of innumerable small molecules, but in
contrast to the other inflammatory systems, there is no
knownmechanism toinhibitthis oxidantradical system,
once it is fully activated.
Phospholipases
There is no evidence that inflammatory cells secrete
phospholipases for cytotoxic purposes. However, as
indicated above, macrophages, when stimulated, ac-
tivate a phospholipase A2 which liberates biologically
activefattyacids, e.g., linoleicacid. Similarly, activation
ofaphospholipase inneutrophilsresultsintheliberation
of hydroxy fatty acids, e.g., 5-hydroxyeicosatetraenoic
and 5,12-dihydroxyeicosatetraenoic. Thus, the function
of these activatable phospholipases is to produce
products which attract specific inflammatory cells.
Neutral Proteases
Neutral proteases, secreted both by activated macro-
phages and by PMNL may be directly involved in tissue
destruction.
The elastase ofPMNL and macrophages (41) destroy
extracellular structures (elastin) (42) whereas the
neutral proteases ofmacrophages are directly cytotoxic
(31). The involvement of inflammatory proteases, e.g.,
neutrophil elastase in clinical lung destruction (emphy-
sema) is now generally accepted (43). Toxic oxidants
such as cigarette smoke, or oxidant radicals, produced
by activated neutrophils, directly inactivate the prote-
ase inhibitor, a1-trypsin inhibitor (5). This destruction
of the natural inhibitor of the elastase results in the
excessive destruction of elastin by neutrophil elastase
with the development of pulmonary emphysema. It is
not clear ifhydrolytic enzymes ofmacrophages are also
involved in pulmonary destruction. These macrophage
cytotoxic proteases may be involved in tumor sur-
veillance (31) or in autoimmune mechanisms which
result in destruction of normal cells (44). It is possible
that pulmonary tissue-specific antigen is involved in
some ofthe many granulomatous pulmonary syndromes
seen in man in which macrophages are the effector cells
present. Example of such syndromes involving tissue
specific antigens in other organs include multiple sclero-
sis (45), thyroiditis (46) and chronic bowel disease (29).
In these various syndromes, it is unclear whether killer
T-lymphocytes or macrophages are the cytotoxic effec-
tor cells and also if neutral hydrolases or oxidant
radicals are the cytotoxic molecules.
REFERENCES
1. Kilburn, K. H., Lynn, W S., Tres, L. L., and McKenzie, W N.
Leukocyte recruitment through airwaywallby condensed vegeta-
ble tannins and quercetin. Lab. Invest. 28: 55-59 (1973).
2. Kimball, R. E., Reddy, K., Pierce, T. H., Schwartz, L. W,
Mastafa, M. G., and Cross, C. E. Oxygen toxicity: augmentation
of antioxidant defense mechanisms in rat lung. Am. J. Physiol.
230: 1425-1431 (1976).
3. Myrvick, Q. N., Leake, E. S., and Farris, B. Studies on
pulmonary alveolar macrophages from the normal rabbits: a
technique to procure them in high state ofpurity. J. Immunol. 86:
128-132 (1961).
4. Wright, R. A., Hiatt, E. R, and Weiss, H. S. Mortality and
histopathology of germ-free rats and mice exposed to 100%
oxygen. Proc. Soc. Exptl. Biol. Med. 122: 446-448 (1966).
5. Brown, C. F., Prath, P C., and Lynn, W S. Characterization
of pulmonary cellular influx differentials to known toxic agents
between species. Inflammation 6: 327-341 (1982).
6. Somayajulu, R. S. N., Mukherjee, S. R, Lynn, W S., and
Bennett, R B. Pulmonary oxygentoxicity inchickens and rabbits.
Undersea Biomed. J. 5: 1-7 (1978).
7. Austen, K. F. Homeostasis ofeffector systems which can also be
recruited for immunological reactions. J. Immunol. 121: 793-805
(1978).
8. Goetzl, E. J., and Pickett, W C. The human PNM leukocyte
chemotactic activity of complex hydroxy-eicosatetraenoic acids
(HETEs). J. Immunol. 125: 1789-1791 (1980).
9. Schiffman, E., and Gallin J. I. Biochemistry of phagocyte
chemotaxis. Curr. Topics Cell. Regul. 15: 203-261 (1979).
10. Turner, S. R., Tainer, J. A., and Lynn, W S. The biogenesis of
chemotactic molecules: afunctionforthearachidoniclipoxygenase
system of platelets. Nature 257: 680-681 (1975).
11. Fernandez, H. N., Henson, P M., Otani, A., and Hugli, T. E.
Chemotactic response to human C3. and C5, anaphylatoxins. I.
Evaluation ofC3, and C5a leukotaxis in vitro and under simulated
in vivo conditions. J. Immunol. 120: 109-115 (1978).CELLULAR INFLUX IN LUNG 311
12. Perez, H. D., Goldstein, I. M., Webster, R. O., and Henson, P M.
Chemotactic activity of C5a des Arg: enhancement by an anionic
polypeptide ("helper factor") in normal human serum (abstract).
Fed. Proc. 39: 1049 (1980).
13. Postlethwaite, A. E., and Kang, A. H. Collagen and collagen
peptide-induced chemotaxis ofhuman blood monocytes. J. Exptl.
Med. 143: 1299-1307 (1976).
14. Senior, R. M., Griffin, G. L., and Mechane, R. P Chemotactic
activity of elastin-derived peptides. J. Clin. Invest. 66: 859-862
(1980).
15. Postlethwaite, A. E., Keski-Oja, J., and Kang, A. H. Chemotac-
tic attraction ofhuman fibroblasts to fibronectin (abstract). Clin.
Res. 27: 646A (1979).
16. Chenoweth, D. E., and Hugli, T. E. Demonstration ofspecific C5a
receptor on intact human polymorphonuclear leukocytes. Proc.
Natl. Acad. Sci. (U.S.) 75: 3343-3349 (1978).
17. Williams, L. T., Snyderman, R., Pike, M. C., and Lefkowitz, R. J.
Specific receptor sites for chemotactic peptides on human poly-
morphonuclear leukocytes. Proc. Natl. Acad. Sci. (U.S.) 74:
1204-1208 (1977).
18. Mukherjee, C., and Lynn, W S. Role of ions and extracellular
protein in leukocyte motility and membrane ruffling. Am. J.
Pathol. 93: 369-381 (1978).
19. Lynn, W S., Jeffs, R, Heald, S., and Mohapatra, N. N2
substituted analogues of chemotactic peptides and leukocyte
function. J. Biol. Chem. in press, (1980).
20. Dahinder, C., and Fehr, J. Receptor-directed inhibition ofchemo-
tactic factor-induced neutrophil hyperactivity by pyrazolon
derivatives. Definition of a chemotactic peptide antagonist. J.
Clin. Invest. 66: 884-891 (1980).
21. Goetzl, E. J., Tashjian, A. H., Rubin, R. H., and Austen, K. F
Production of a low molecular weight eosinophil polymorphonu-
clear leukocyte chemotactic factor by anaplastic squamous cell
carcinomas ofthe humanlung. J. Clin. Invest. 61: 770-780(1978).
22. Hunninghake, G. W, Gadek, J. E., Young, R. C., Kawanami, O.,
Ferrans, V J., and Crystal, R. G. Maintenance of granuloma
formation in pulmonary sarcoidosis by T-lymphocytes within the
lung. N. Engl. J. Med. 301: 594-597 (1980).
2l. Kay, A. B., Steckshulte, D. J., and Austen, K. F An eosinophil
leukocyte chemotactic factor of anaphylaxis. J. Exptl. Med. 133:
602-619 (1971).
24. Kazmierowski, J. A., Gallin, J. I., and Reynolds, H. Y Mecha-
nism forthe inflammatory response inprimate lungs. Demonstra-
tion and partial characterization of an alveolar macrophage-
derived chemotactic factor with preferential activity for poly-
morphonuclear leukocytes. J. Clin. Invest. 59: 273-281 (1977).
25. Hunninghake, G. W, Gadek, J. E., Fales, H. M., and Crystal, R.
G. Human alveolar macrophage-derived chemotactic factor for
neutrophils. J. Clin. Invest. 66: 473-483 (1980).
26. Freeman, B. A., and Lynn, W S. Fatty acid secretion and
metabolism in "activated" rabbit alveolar macrophages. Biochem.
Biophys. Acta 620: 528-537 (1980).
27. Lynn, W S., Somayajulu, R., Sahu, S., and Selph, J. Character-
ization of chemotactic agents produced in experimental pleural
inflammation. In: Chemotaxis of Human Neutrophils and Mono-
cytes. (KROC Foundation Symposium, Jan. 29-Feb. 2, 1977),
Raven Press, New York, 1977.
28. Ford-Hutchinson, A. W, Bray, M. A., Doig, M. V, Shipley, M. E.,
and Smith, M. J. H. Leukotriene B, a potent chemokinetic and
aggregating substance released from polymorphonuclear leuko-
cytes. Nature 286: 264-265 (1980).
29. Roche, J. K., Cook, S. L., Day, E. D. Goblet cell glycoprotein: an
organ-specific antigen for gut. Isolation, tissue localization, and
immune response in inbred rats. Immunology 44: 799-810 (1981).
30. Hammerstrom, S., Hamberg, M., Samuelsson, B., Duell, E.,
Stawiski, M., and Vorhees, J. Increased concentrations of
nonesterifiedarachidonicacid, 12L-hydroxy-5,8,10,14-eicosatetra-
enoic acid, prostaglandin E2 and prostaglandin F2- in epidermis
of psorasis. Proc. Natl. Acad. Sci. (U.S.) 72: 5130-5134 (1975).
31. Adams, D. 0. Kao, K. J., Farb, R., and Pizzo, S. V Effector
mechanisms of cytolytically activated macrophages. I. Secretion
ofneutral proteases and effect ofprotease inhibitors. J. Immunol.
124: 286-292 (1980).
32., Hirata, F., Schiffmann, E., Venkatasubramanian, K., Salomon,
D., and Axelrod, J. A phospholipase A2 inhibitory protein in
rabbit neutrophils induced by glucocorticoids. Proc. Natl. Acad.
Sci. (U.S.) 77: 2533-2536 (1980).
33. Stevens, J. B., and Autor, A. P Proposed mechanisms for
neonatal rat tolerance to normobaric hyperoxia. Fed. Proc. 39:
3138-3143 (1980).
34. Babior, B. M. Oxygen dependent microbial killing by phagocytes.
N. Engl. J. Med. 298: 659-667 (1978).
35. Stevens, J. B., and Autor, A. P Oxygen-induced synthesis of
pulmonary copper/zinc superoxide dismutase: extracellular loca-
tion. J. Clin. Invest. in press.
36. Becker, E. L., and Stossel, T. P. Chemotaxis (abstract). Fed.
Proc. 39: 2949-2952 (1980).
37. Cohen, H. J., and Chovaniec, M. E. Superoxide generation by
digitonin-stimulated guinea pig granulocytes. J. Clin. Invest. 61:
1081-1088 (1978).
38. Borregaard, N., and Kragballe, K. Role of oxygen in antibody-
dependent cytotoxicity mediated by monocytes and neutrophils.
J. Clin. Invest. 66: 676-683 (1980).
39. Halliwell, B. Superoxide-dependent formation of hydroxyl radi-
cals in the presence of iron salts. FEBS Letters 96: 238-242
(1978).
40. Thnswell, A. K., and Lynn, W S. A displaceable surface-bound
superoxide stimulating factor on circulating human polymorpho-
nuclearleukocytes. Biochem. Biophys. Res. Commun. 90: 911-916
(1979).
41. White, R., Lin, H. -S., and Kuhn, C., III. Elastase secretion by
peritoneal exudative and alveolar macrophages. J. Exptl. Med.
146: 802-808 (1977).
42. Janoff, A., Carp, H., Lee, D. K., and Drew, R. T. Cigarette
smoke inhalation decrease alpha-1-antitrypsin activity in rat
lung. Science 206: 1313-1314 (1979).
43. Carp, H., and Janoff, A. Potential mediator of inflammation.
Phagocyte-derived oxidants suppress the elastase-inhibitory ca-
pacity ofalpha1-proteinase inhibitor in vitro. J. Clin. Invest. 66:
987-995 (1980).
44. Patterson, P Y. Transfer of allergic encophalomyelitis in rats by
means of lymph node cells J. Exptl. Med. 111: 119-135 (1960).
45. APatterson, P Y Experimental allergic encephalomyelitis and
autoimmune disease. Adv. Immunol. 5: 131-208 (1966).
46. Beall, G. N., and Solomon, D. H. Hashimoto's disease and Grave's
disease. In: Immunological Diseases (M. Samter, Ed.), Little,
Brown, and Co., Boston, 1978, pp. 1261-1267.